Information Provided By:
Fly News Breaks for October 24, 2016
ALNY
Oct 24, 2016 | 06:54 EDT
Piper Jaffray analyst Edward Tenthoff says shares of Alnylam Pharmaceuticals are down 48% since the company said it was discontinuing the Phase III ENDEAVOR trial of revusiran. The analyst believes the death imbalance in the trial was either a revusiran specific or hATTR-CM disease issue that does not apply to the rest of Alnylam's RNAi pipeline. He recommends owning the stock now and reiterates an Overweight rating on Alnylam with a $106 price target.
News For ALNY From the Last 2 Days
There are no results for your query ALNY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.